Certain mucin epitopes are associated with tumors and are detected within the tandem repeat core of human mucin glycoprotein, MUC1, from malignant cells but not normal cells. Most of the known anti-MUC1 antibodies (Abs) recognize epitopes with the APDTRPAPG region of tandem repeat core, which is known as an immunodominant (ID) region of the MUC1. A new structural model of this ID-region is proposed based on NMR data. The Thr residue within the DTR motif of tandem repeat is O-glycosylated in vivo. Some Abs to MUC1 have shown a higher affinity to the DTR motif when Thr is glycosylated with core-type glycans. The attachment of peptide epitopes to the C-terminal effector region of the human C5a anaphylatoxin has been shown to improve the delivery of these antigens and simultaneously stimulate an immune response. Based on these findings, new MUC1-like immunogenic peptides with enhanced tumor selectivity will be developed to be used as immunogens for tumor vaccines and for producing immunodiagnostic reagents with improved selectivity. The structural model will be used to design, synthesize, and test conformationally constrained MUC1-like peptides and peptidomimetics with enhanced immunogenicity. The structural features of the carcinoma-associated epitopes (peptide and carbohydrate) in the ID-region of the MUC1 tandem repeat core will be evaluated by optical (ECD, FTIR, VCD) and NMR spectroscopy and by molecular modeling methods. To enhance epitope-specific Ab and/or cellular responses to the MUC1-like peptides, molecular constructs that include peptide and immunoadjuvant moieties will be designed and synthesized. A potent analog of the C-terminal effector region of the human C5a, YSFKPMPLaR, will be used as a molecular adjuvant. The immunogenecity of the MUC1 epitopes will be evaluated in vitro and in vivo. It was shown recently that human carcinoma cells contain an alternative sequence variant (substitutions of Asp by Glu) at a high incidence in the PDTR fragment. The origin and incidence of mutations in the ID-region of the MUC1 and the effects of these mutations on structure, antigenicity, and immunogenicity of tandem repeat peptides will be investigated. The existence of tumor-associated sequence variants raises the possibility for their use as immunogens for the generation of immunodiagnostic reagents with a higher degree of tumor selectivity and their application to therapy as more specific and efficient vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084106-05
Application #
6696353
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Howcroft, Thomas K
Project Start
2000-03-16
Project End
2005-12-31
Budget Start
2004-01-01
Budget End
2005-12-31
Support Year
5
Fiscal Year
2004
Total Cost
$356,020
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Ninkovic, Tanja; Kinarsky, Leo; Engelmann, Katja et al. (2009) Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 47:131-40
Ninkovic, Tanja; Hanisch, Franz-Georg (2007) O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 179:2380-8
Parry, Simon; Hanisch, Franz Georg; Leir, Shih-Hsing et al. (2006) N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology 16:623-34
Carlos, Casey A; Dong, Hui Fang; Howard, O M Zack et al. (2005) Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175:1628-35
Palmai-Pallag, Timea; Khodabukus, Naila; Kinarsky, Leo et al. (2005) The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane-tethered mucins. FEBS J 272:2901-11
von Mensdorff-Pouilly, Silvia; Kinarsky, Leo; Engelmann, Katja et al. (2005) Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 15:735-46
Pisarev, Vladimir M; Kinarsky, Leo; Caffrey, Thomas et al. (2005) T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. Int Immunopharmacol 5:315-30
Engelmann, Katja; Kinlough, Carol L; Muller, Stefan et al. (2005) Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles. Glycobiology 15:1111-24
Pisarev, Vladimir; Yu, Bin; Salup, Raoul et al. (2003) Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9:6523-33
Heuser, C; Ganser, M; Hombach, A et al. (2003) An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. Br J Cancer 89:1130-9

Showing the most recent 10 out of 15 publications